% alzhub.org library filter
% Source: https://alzhub.org/research?institution=I168537998&design=trial
% 15 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{zimmer2025-40063015,
  author  = {Zimmer, J. A. and Ardayfio, P. and Wang, H. and Khanna, R. and Evans, C. D. and Lu, M. and Sparks, J. and Andersen, S. and Lauzon, S. and Nery, E. S. M. and others},
  title   = {{Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials}},
  journal = {JAMA Neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2025.0065},
  pmid    = {40063015},
  url     = {https://doi.org/10.1001/jamaneurol.2025.0065}
}

@article{honig2018-29365294,
  author  = {Honig, L. S. and Vellas, B. and Woodward, M. and Boada, M. and Bullock, R. and Borrie, M. and Hager, K. and Andreasen, N. and others},
  title   = {{Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2018},
  doi     = {10.1056/nejmoa1705971},
  pmid    = {29365294},
  url     = {https://doi.org/10.1056/nejmoa1705971}
}

@article{mintun2021-33720637,
  author  = {Mintun, M. A. and Lo, A. C. and Duggan Evans, C. and Wessels, A. M. and Ardayfio, P. A. and Andersen, S. W. and Shcherbinin, S. and Sparks, J. and others},
  title   = {{Donanemab in Early Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2021},
  doi     = {10.1056/nejmoa2100708},
  pmid    = {33720637},
  url     = {https://doi.org/10.1056/nejmoa2100708}
}

@article{wessels2020-31764959,
  author  = {Wessels, A. M. and Tariot, P. N. and Zimmer, J. A. and Selzler, K. J. and Bragg, S. M. and Andersen, S. W. and Landry, J. and Krull, J. H. and others},
  title   = {{Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials}},
  journal = {JAMA neurology},
  year    = {2020},
  doi     = {10.1001/jamaneurol.2019.3988},
  pmid    = {31764959},
  url     = {https://doi.org/10.1001/jamaneurol.2019.3988}
}

@article{wang2025-40172303,
  author  = {Wang, H. and Serap Monkul Nery, E. and Ardayfio, P. and Khanna, R. and Otero Svaldi, D. and Gueorguieva, I. and Shcherbinin, S. and Andersen, S. W. and Hauck, P. M. and Engle, S. E. and others},
  title   = {{Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70062},
  pmid    = {40172303},
  url     = {https://doi.org/10.1002/alz.70062}
}

@article{lu2025-41082199,
  author  = {Lu, M. and Kim, M. J. and Collins, E. C. and Shcherbinin, S. and Ellinwood, A. K. and Yokoi, Y. and Brooks, D. A. and Hansson, O. and others},
  title   = {{Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2025.3869},
  pmid    = {41082199},
  url     = {https://doi.org/10.1001/jamaneurol.2025.3869}
}

@article{shcherbinin2022-36094645,
  author  = {Shcherbinin, S. and Evans, C. D. and Lu, M. and Andersen, S. W. and Pontecorvo, M. J. and Willis, B. A. and Gueorguieva, I. and Hauck, P. M. and others},
  title   = {{Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.2793},
  pmid    = {36094645},
  url     = {https://doi.org/10.1001/jamaneurol.2022.2793}
}

@article{sims2023-37459141,
  author  = {Sims, JR. and Zimmer, J. A. and Evans, C. D. and Lu, M. and Ardayfio, P. and Sparks, J. and Wessels, A. M. and Shcherbinin, S. and others},
  title   = {{Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2023},
  doi     = {10.1001/jama.2023.13239},
  pmid    = {37459141},
  url     = {https://doi.org/10.1001/jama.2023.13239}
}

@article{fleisher2024-38386949,
  author  = {Fleisher, A. S. and Munsie, L. M. and Perahia, D. G. S. and Andersen, S. W. and Higgins, I. A. and Hauck, P. M. and Lo, A. C. and Sims, JR. and others},
  title   = {{Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease}},
  journal = {Neurology},
  year    = {2024},
  doi     = {10.1212/wnl.0000000000208061},
  pmid    = {38386949},
  url     = {https://doi.org/10.1212/wnl.0000000000208061}
}

@article{fleisher2026-42441396,
  author  = {Fleisher, Adam S and Munsie, Leanne and Mancini, Michele and Cheng, Yun-Ju and Guo, Jiaying and Nuthall, Hugh and Otero, Diana Svaldi and Kotari, Vikas and others},
  title   = {{Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2026},
  doi     = {10.1001/jama.2026.12768},
  pmid    = {42441396},
  url     = {https://doi.org/10.1001/jama.2026.12768}
}

@article{atri2026-42128444,
  author  = {Atri, A. and Apostolova, L. G. and Iwata, A. and Wessels, A. M. and Atkins, A. and Lu, M. and Ye, W. and Ryan, S. and Doty, E. G.},
  title   = {{Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial}},
  journal = {Neurology: Clinical Practice},
  year    = {2026},
  doi     = {10.1212/CPJ.0000000000200621},
  pmid    = {42128444},
  url     = {https://doi.org/10.1212/CPJ.0000000000200621}
}

@article{liuseifert2015-26402769,
  author  = {Liu-Seifert, H. and Siemers, E. and Price, K. and Han, B. and Selzler, K. J. and Henley, D. and Sundell, K. and Aisen, P. and others},
  title   = {{Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2015},
  doi     = {10.3233/jad-142508},
  pmid    = {26402769},
  url     = {https://doi.org/10.3233/jad-142508}
}

@article{wong2010-20501908,
  author  = {Wong, D. F. and Rosenberg, P. B. and Zhou, Y. and Kumar, A. and Raymont, V. and Ravert, H. T. and Dannals, R. F. and Nandi, A. and others},
  title   = {{In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)}},
  journal = {Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year    = {2010},
  doi     = {10.2967/jnumed.109.069088},
  pmid    = {20501908},
  url     = {https://doi.org/10.2967/jnumed.109.069088}
}

@article{collins2026-42565262,
  author  = {Collins, E. C. and Lu, M. and Beck, R. and Hendrix, J. and Hodsdon, M. E. and Hansson, O.},
  title   = {{Plasma P-tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease}},
  journal = {Alzheimer's \& Dementia},
  year    = {2026},
  doi     = {10.1002/alz.71740},
  pmid    = {42565262},
  url     = {https://doi.org/10.1002/alz.71740}
}

@article{tunali2025-40081955,
  author  = {Tunali, Ilke and Wang, Jian and Arora, Anupa and Kim, Min Jung and Shcherbinin, Sergey and Pontecorvo, Michael J. and Iaccarino, Leonardo},
  title   = {{Development and Validation of a 18 F-Flortaucipir PET Visual Stratification Method}},
  journal = {Journal of Nuclear Medicine},
  year    = {2025},
  doi     = {10.2967/jnumed.124.268700},
  pmid    = {40081955},
  url     = {https://doi.org/10.2967/jnumed.124.268700}
}